California Healthcare Institute Expands Sacramento Staff; Board Appoints New Chairman-Elect, Board Members

Veteran biomedical leaders to help guide CHI policy agenda

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

La Jolla, Calif. (PRWEB) July 19, 2012

CHI-California Healthcare Institute announced today the nomination of David E.I. Pyott, chairman of the board, president and chief executive officer of Allergan, Inc., to serve as chairman-elect of the CHI board of directors. CHI’s board also elected new members Daniel J. McIntyre, senior vice president of public affairs for Biogen Idec, and Maulik Navanaty, president of Boston Scientific’s Neuromodulation division. Additionally, CHI announced the appointment of Victoria C. Stewart as associate director of state government affairs in CHI’s Sacramento office. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

“In a turbulent economy, the California biomedical community confronts serious questions about our future,” said David L. Gollaher, Ph.D., CHI president and CEO. “Strong industry leadership is essential to guiding CHI’s approach to the important issues facing the biomedical community today. From coverage and reimbursement to regulation and research funding, we are facing one of the toughest environments in CHI’s 20-year history. These seasoned executives will help guide CHI’s policy agenda and ensure we are well prepared for the next 20 years.”

Pyott was elected to the CHI board in 1998, serving as its chairman in 2003-04. During his chairmanship, he was instrumental in strengthening CHI’s board and the organization’s financial position as well as focusing its political agenda in Washington and Sacramento.
Pyott joined Allergan in January 1998 as president and CEO. That same year, he refocused the company’s strategy on specialty pharmaceuticals as well as on restructuring Allergan’s worldwide operations. Savings from these streamlining programs were reinvested into a major expansion of R&D and sales forces worldwide. Further focusing of Allergan on creating leading specialty pharmaceutical franchises, in ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets was realized in 2002 with the spinoff of the ophthalmic surgical device and contact lens care businesses into Advanced Medical Optics, Inc., a separate, publicly traded company. In March 2006, Allergan acquired Inamed Corp. for approximately $3 billion to create the world’s largest medical aesthetics company. He was elected to the position of chairman of the board of Allergan in April 2001. In June 2006, Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgment of his contribution to British business excellence and management skills in the United States. He holds a law degree from the Europa Institute at the University of Amsterdam, a master’s degree from the University of Edinburgh, and a master of business administration from the London Business School.

As senior vice president of public affairs for Biogen Idec, McIntyre is responsible for global communication, government affairs, employee communication and community relations. He also serves on the board of directors of the Biogen Idec Foundation and is treasurer of the company’s political action committee. McIntyre’s experience in public and government affairs on high-profile issues covers medical product safety and supply; screening and access to therapies in at-risk communities; conduct and reimbursement of clinical trials in the U.S. and developing countries; and pricing of pharmaceutical and biotechnology therapies. McIntyre serves on the executive committee of the Rutgers University Foundation, and is a past member of the boards of Caldwell College, the American Association for World Health, the New England Healthcare Institute (NEHI), and Connecticut United for Research Excellence (CURE). He is a graduate of Seton Hall University and holds a master of public administration degree from Rutgers University, where he received the E. Drexel Godfrey Award for Academic Excellence.

Nanavaty is senior vice president and president of the neuromodulation division for Boston Scientific and a member of its executive committee. In this role, he is responsible for the innovation leader in less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain. Prior to his current role, Nanavaty was president and representative director of Boston Scientific Japan responsible for cardiovascular, rhythm management, endosurgery and urology businesses. Previously, he was vice president and general manager of the company’s interventional cardiology business in Japan. During his tenure, Nanavaty managed the successful expansion of cardiology business there. He joined Boston Scientific in 2005 as vice president of corporate strategy for Japan, where he lead business transformation and increased operational efficiency. Prior to joining Boston Scientific, Nanavaty spent 16 years working in various executive positions at Baxter International Inc. including Baxter Japan. Nanavaty earned his doctorate in pharmaceutical sciences from the University of Illinois and his master’s in business administration from the University of Chicago.

Stewart will report to CHI’s Vice President of State Government Affairs Consuelo Hernandez and will lobby bills, develop and implement outreach/education and legislative advocacy programs, and build and maintain alliances with CHI member companies, partner associations and other affiliate organizations. She most recently served as the capitol director for Assemblyman Curt Hagman. There, she oversaw all major legislation and staffed multiple committees. Stewart is a graduate of California State University, Sacramento with a bachelor’s degree in political science.

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.


Contact